NASDAQ
7.95USD
+0.21 (+2.71%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.3B
P/E
—
EPS
—
Beta
2.43
52W range
6.2-11.97
Day range
7.59–8.09
Open
7.75
Prev close
7.74
Volume
5.6M
Avg volume
4.7M
Dividend
0.00
IPO
1995-12-05
https://seekingalpha.com/article/4926628-novavax-the-beaten-down-covid-19-darling · 7/29/2026+0.60
https://247wallst.com/investing/2026/05/11/moderna-stock-is-up-6-today-is-it-outperforming-other-vaccine-stocks-like-pfizer-and-novavax/ · 5/11/2026+0.10
https://www.zacks.com/stock/news/2913376/novavax-nvax-beats-stock-market-upswing-what-investors-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2913376 · 5/1/2026-0.60
https://www.zacks.com/stock/news/2912931/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_earnings_esp-2912931 · 5/1/2026+0.00
https://www.zacks.com/stock/news/2897756/novavax-nvax-beats-stock-market-upswing-what-investors-need-to-know · 4/9/2026
https://www.zacks.com/stock/news/2893330/novavax-nvax-stock-dips-while-market-gains-key-facts?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2893330 · 4/1/2026-0.60
https://www.benzinga.com/markets/earnings/26/02/50904546/covid-19-vaccine-maker-novavax-swings-to-profit-as-sales-climb · 2/26/2026+0.60
https://www.zacks.com/stock/news/2870299/is-most-watched-stock-novavax-inc-nvax-worth-betting-on-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2870299 · 2/17/2026+0.30
https://www.zacks.com/stock/news/2822549/novavax-inc-nvax-is-a-trending-stock-facts-to-know-before-betting-on-it?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2822549 · 1/26/2026+0.40
https://www.zacks.com/stock/news/2821519/novavax-nvax-stock-dips-while-market-gains-key-facts?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2821519 · 1/22/2026-0.20
https://www.zacks.com/stock/news/2820479/novavax-grants-license-for-use-of-matrix-m-adjuvant-to-pfizer?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2820479 · 1/21/2026+0.80
https://seekingalpha.com/article/4859967-novavax-inc-nvax-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript · 1/15/2026+0.10
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
